JP2023540796A5 - - Google Patents
Info
- Publication number
- JP2023540796A5 JP2023540796A5 JP2023516053A JP2023516053A JP2023540796A5 JP 2023540796 A5 JP2023540796 A5 JP 2023540796A5 JP 2023516053 A JP2023516053 A JP 2023516053A JP 2023516053 A JP2023516053 A JP 2023516053A JP 2023540796 A5 JP2023540796 A5 JP 2023540796A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cdr1
- cdr2
- cdr3
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024155472A JP2025003970A (ja) | 2020-09-11 | 2024-09-10 | ベータ鎖媒介性免疫を調節するための方法及び組成物 |
Applications Claiming Priority (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077387P | 2020-09-11 | 2020-09-11 | |
| US202063077314P | 2020-09-11 | 2020-09-11 | |
| US202063077397P | 2020-09-11 | 2020-09-11 | |
| US63/077,387 | 2020-09-11 | ||
| US63/077,397 | 2020-09-11 | ||
| US63/077,314 | 2020-09-11 | ||
| US202063104265P | 2020-10-22 | 2020-10-22 | |
| US202063104247P | 2020-10-22 | 2020-10-22 | |
| US202063104220P | 2020-10-22 | 2020-10-22 | |
| US63/104,265 | 2020-10-22 | ||
| US63/104,220 | 2020-10-22 | ||
| US63/104,247 | 2020-10-22 | ||
| US202163142930P | 2021-01-28 | 2021-01-28 | |
| US202163142940P | 2021-01-28 | 2021-01-28 | |
| US202163142944P | 2021-01-28 | 2021-01-28 | |
| US63/142,930 | 2021-01-28 | ||
| US63/142,944 | 2021-01-28 | ||
| US63/142,940 | 2021-01-28 | ||
| US202163165053P | 2021-03-23 | 2021-03-23 | |
| US63/165,053 | 2021-03-23 | ||
| US202163176112P | 2021-04-16 | 2021-04-16 | |
| US63/176,112 | 2021-04-16 | ||
| US202163237972P | 2021-08-27 | 2021-08-27 | |
| US63/237,972 | 2021-08-27 | ||
| PCT/US2021/049761 WO2022056192A1 (en) | 2020-09-11 | 2021-09-10 | Methods and compositions for modulating beta chain mediated immunity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024155472A Division JP2025003970A (ja) | 2020-09-11 | 2024-09-10 | ベータ鎖媒介性免疫を調節するための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540796A JP2023540796A (ja) | 2023-09-26 |
| JP2023540796A5 true JP2023540796A5 (https=) | 2024-09-19 |
Family
ID=80629876
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516053A Withdrawn JP2023540796A (ja) | 2020-09-11 | 2021-09-10 | ベータ鎖媒介性免疫を調節するための方法及び組成物 |
| JP2024155472A Pending JP2025003970A (ja) | 2020-09-11 | 2024-09-10 | ベータ鎖媒介性免疫を調節するための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024155472A Pending JP2025003970A (ja) | 2020-09-11 | 2024-09-10 | ベータ鎖媒介性免疫を調節するための方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11965024B2 (https=) |
| EP (1) | EP4211170A4 (https=) |
| JP (2) | JP2023540796A (https=) |
| KR (2) | KR20240142592A (https=) |
| AU (1) | AU2021339754A1 (https=) |
| CA (1) | CA3194968A1 (https=) |
| IL (1) | IL301254A (https=) |
| MX (1) | MX2023002948A (https=) |
| TW (1) | TW202227495A (https=) |
| UY (1) | UY39415A (https=) |
| WO (1) | WO2022056192A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021010857A (es) | 2019-03-11 | 2021-12-15 | Janssen Biotech Inc | Anticuerpos biespecificos anti-v(beta17)/anti-cd123. |
| WO2022056197A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| TW202227495A (zh) | 2020-09-11 | 2022-07-16 | 美商健生生物科技公司 | 用於調節β鏈介導之免疫的方法及組成物 |
| JP2024507180A (ja) * | 2021-02-16 | 2024-02-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体 |
| CN114940710B (zh) * | 2022-06-07 | 2023-09-26 | 恺佧生物科技(上海)有限公司 | 一种提高重组人psma蛋白表达的方法 |
| WO2026035888A1 (en) * | 2024-08-06 | 2026-02-12 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221352B1 (en) * | 1989-03-21 | 2001-04-24 | The Immune Response Corporation | Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells |
| US6413516B1 (en) * | 1989-03-21 | 2002-07-02 | The Immune Response Corporation | Peptides and methods against psoriasis |
| FR2681875A1 (fr) * | 1991-09-26 | 1993-04-02 | Immunotech Sa | Nouvelles molecules de adn recombinants contenant la partie codante d'une chaine vb17 du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant. |
| US6084087A (en) | 1991-09-27 | 2000-07-04 | New York Society For The Ruptured And Crippled Maintaing The Hospital For Special Surgery | DNA encoding conserved T-cell receptor sequences |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| PT1015576E (pt) | 1997-09-16 | 2005-09-30 | Egea Biosciences Llc | Metodo para a sintese quimica completa e montagem de genes e de genomas |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| EP1877075A4 (en) | 2005-04-25 | 2008-07-30 | Pfizer | ANTIBODY TO MYOSTATIN |
| US7585960B2 (en) | 2005-05-11 | 2009-09-08 | Theramab Gmbh | Nucleic acids encoding superagonistic anti-CD28 antibodies |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| US9315577B2 (en) | 2008-05-01 | 2016-04-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| US20110097339A1 (en) | 2008-07-18 | 2011-04-28 | Domantis Limited | Compositions monovalent for CD28 binding and methods of use |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| BR112012031727B1 (pt) | 2010-06-15 | 2022-03-29 | Genmab A/S | Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo |
| NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US9790274B2 (en) | 2013-03-14 | 2017-10-17 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases |
| NZ759969A (en) | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| SG10201913782UA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| MA40609B1 (fr) | 2014-09-05 | 2020-05-29 | Janssen Pharmaceutica Nv | Agents de liaison cd123 et leurs utilisations |
| EP3215538A4 (en) * | 2014-11-07 | 2018-07-04 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
| CA2979759C (en) | 2015-04-16 | 2023-08-08 | Eisai R&D Management Co., Ltd. | Anti-human notch4 antibody |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| GB201516272D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
| EP3356415B1 (en) | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| TWI790206B (zh) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| WO2018112407A1 (en) | 2016-12-15 | 2018-06-21 | Duke University | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors |
| US11370830B2 (en) | 2017-04-07 | 2022-06-28 | The Rockefeller University | Neutralizing antibodies that bind to the zika virus domain III envelope region |
| KR20200041834A (ko) | 2017-06-01 | 2020-04-22 | 젠코어 인코포레이티드 | Cd123 및 cd3에 결합하는 이중특이성 항체 |
| JP7404252B2 (ja) | 2017-11-08 | 2023-12-25 | ヤフェイ シャンハイ バイオロジー メディスン サイエンス アンド テクノロジー カンパニー リミテッド | 生体分子のコンジュゲートおよびその使用 |
| MX2020014243A (es) | 2018-06-19 | 2021-05-12 | Biontech Us Inc | Neoantigenos y usos de los mismos. |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| GB2595980B (en) | 2019-01-04 | 2023-06-14 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| MX2021010857A (es) | 2019-03-11 | 2021-12-15 | Janssen Biotech Inc | Anticuerpos biespecificos anti-v(beta17)/anti-cd123. |
| EP3986936A4 (en) | 2019-06-21 | 2023-03-15 | Single Cell Technology, Inc. | ANTI-TIGIT ANTIBODIES |
| AU2020359070A1 (en) | 2019-10-03 | 2022-04-21 | Janssen Biotech, Inc. | Methods for producing biotherapeutics with increased stability by sequence optimization |
| AU2021225870A1 (en) | 2020-02-27 | 2022-10-20 | Janssen Biotech, Inc. | Materials and methods for modulating an immune response |
| WO2022056197A1 (en) * | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| TW202227495A (zh) | 2020-09-11 | 2022-07-16 | 美商健生生物科技公司 | 用於調節β鏈介導之免疫的方法及組成物 |
| US20220089737A1 (en) | 2020-09-11 | 2022-03-24 | Janssen Biotech, Inc. | Multi-specific immune targeting molecules and uses thereof |
-
2021
- 2021-09-10 TW TW110133807A patent/TW202227495A/zh unknown
- 2021-09-10 KR KR1020247030846A patent/KR20240142592A/ko active Pending
- 2021-09-10 EP EP21867632.8A patent/EP4211170A4/en active Pending
- 2021-09-10 WO PCT/US2021/049761 patent/WO2022056192A1/en not_active Ceased
- 2021-09-10 UY UY0001039415A patent/UY39415A/es unknown
- 2021-09-10 MX MX2023002948A patent/MX2023002948A/es unknown
- 2021-09-10 AU AU2021339754A patent/AU2021339754A1/en active Pending
- 2021-09-10 CA CA3194968A patent/CA3194968A1/en active Pending
- 2021-09-10 IL IL301254A patent/IL301254A/en unknown
- 2021-09-10 JP JP2023516053A patent/JP2023540796A/ja not_active Withdrawn
- 2021-09-10 KR KR1020237012247A patent/KR20230084508A/ko active Pending
- 2021-09-10 US US17/472,198 patent/US11965024B2/en active Active
-
2024
- 2024-03-19 US US18/609,023 patent/US12492256B2/en active Active
- 2024-09-10 JP JP2024155472A patent/JP2025003970A/ja active Pending
-
2025
- 2025-11-10 US US19/384,869 patent/US20260103521A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023540796A5 (https=) | ||
| US20220306739A1 (en) | Materials and methods for modulating an immune response | |
| RU2504553C2 (ru) | Антитела к her | |
| JP2011505875A5 (https=) | ||
| JP2023540799A5 (https=) | ||
| JP2020534250A5 (https=) | ||
| JP2012254083A5 (https=) | ||
| US20210284731A1 (en) | Methods and materials for modulating an immune response | |
| JP2023515199A5 (https=) | ||
| US12492256B2 (en) | Methods and compositions for modulating beta chain mediated immunity | |
| JP2024531409A5 (https=) | ||
| US20260055185A1 (en) | Materials and methods for modulating delta chain mediated immunity | |
| JP2019536469A5 (https=) | ||
| ES3062709T3 (en) | Treatment of t cell lymphoma | |
| RU2023108868A (ru) | Способы и композиции для модуляции опосредованного бета-цепью иммунитета | |
| JP2021521201A5 (https=) | ||
| AU2020331879C1 (en) | Treatment of cancer with a combination of an antibody that binds LGR5 and EGFR and a topoisomerase I inhibitor. | |
| US20240336689A1 (en) | Treatment of cancers with an antibody that binds lgr5 and egfr | |
| WO2021215926A1 (en) | Treatment of cancers with an antibody that binds lgr5 and egfr | |
| EP4110390A1 (en) | Materials and methods for modulating an immune response | |
| WO2025220690A1 (ja) | Ｔ細胞腫瘍以外の悪性腫瘍患者に有効な二重特異性抗体 | |
| JPWO2022270523A5 (https=) | ||
| TW202608924A (zh) | 對ｔ細胞腫瘤以外之惡性腫瘤病患有效之雙特異性抗體 | |
| BR122024018564A2 (pt) | Anticorpo multiespecífico e seu uso, composição farmacêutica, seu método de produção e seu uso, ácido nucleico, vetor, célula hospedeira, e kit | |
| AU2022444380A1 (en) | Anti-cd73 antibodies and use thereof |